Skip to content
All Sections
Subscribe Now
66°F
Sunday, August 18th 2024
Today's E-Edition
Home Page
Close Menu
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
SUBSCRIBE NOW
Close Menu
Morning Report in your inbox!
Sign Up
Subscribe
Account Settings
Contact Us
Log Out
Spoof a user
Morning Report in your inbox!
Sign Up
Subscribe
Search
Silicon Valley
66°F
Sunday, August 18th 2024
Today's E-Edition
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AVROBIO, Inc.
< Previous
1
2
Next >
AVROBIO and Tectonic Therapeutic Announce Merger
January 30, 2024
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Explore Strategic Alternatives
July 12, 2023
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million
June 12, 2023
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
May 22, 2023
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting
May 18, 2023
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Leadership Transition
May 01, 2023
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
March 23, 2023
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference
March 03, 2023
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023
February 09, 2023
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2023
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
December 07, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Share Comprehensive Gaucher Disease Program Update
November 17, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit
November 07, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
October 27, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis
October 25, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
October 18, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development
October 11, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 06, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
September 27, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis
September 20, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial
September 14, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Participate in Four Upcoming Investor Conferences in September
August 31, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Participate in Two Upcoming Investor Conferences in August
August 01, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
July 13, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close